L3VLUP
ProSign in

ENTA · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ENTAVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ENTA
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterENTAVRTX
Q3 20206 holders, $163m31 holders, $21.9bn
Q4 20206 holders, $144m30 holders, $18.4bn
Q1 20216 holders, $170m31 holders, $15.4bn
Q2 20215 holders, $143m30 holders, $12.7bn
Q3 20214 holders, $171m35 holders, $10.1bn
Q4 20214 holders, $183m28 holders, $12.4bn
Q1 20225 holders, $163m23 holders, $16.1bn
Q2 20223 holders, $74m25 holders, $18.1bn
Q3 20222 holders, $80m22 holders, $18.4bn
Q4 20222 holders, $72m28 holders, $18.4bn
Q1 20232 holders, $63m26 holders, $21.4bn
Q2 20232 holders, $41m27 holders, $24.7bn
Q3 20234 holders, $28m33 holders, $24.3bn
Q4 20233 holders, $28m32 holders, $28.6bn
Q1 20243 holders, $52m31 holders, $29.8bn
Q2 20243 holders, $39m29 holders, $33.4bn
Q3 20242 holders, $31m27 holders, $33.5bn
Q4 20241 holders, $12m26 holders, $28.5bn
Q1 20252 holders, $12m21 holders, $35.4bn
Q2 20252 holders, $17m21 holders, $32.3bn
Q3 20253 holders, $37m22 holders, $25.9bn
Q4 20254 holders, $118m26 holders, $31.8bn
Q1 20262 holders, $84m25 holders, $31.8bn
Q2 20263 holders, $104m26 holders, $34.6bn
ENTA

Enanta Pharmaceuticals Inc

Holders
3
Reported value
$39m
Buyers
0
Sellers
2

Breadth -2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ENTA (1)

Farallon Capital Management LLC

Only VRTX (27)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →